Breaking News Instant updates and real-time market news.

DTIL

Precision BioSciences

$12.00

-0.97 (-7.48%)

, RHHBY

Roche

$0.00

(0.00%)

06:33
06/12/19
06/12
06:33
06/12/19
06:33

Precision BioSciences names Dario Scimeca as General Counsel

Precision BioSciences (DTIL) announced that Dario Scimeca has joined Precision BioSciences as General Counsel. Prior to joining Precision BioSciences, Scimeca served as associate general counsel for Genentech (RHHBY).

DTIL

Precision BioSciences

$12.00

-0.97 (-7.48%)

RHHBY

Roche

$0.00

(0.00%)

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

DTIL Precision BioSciences
$12.00

-0.97 (-7.48%)

04/22/19
GSCO
04/22/19
INITIATION
Target $24
GSCO
Buy
Precision BioSciences initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter started Precision BioSciences with a Buy rating and $24 price target. The company's value proposition is driven by the allogeneic CAR T portfolio in blood cancers, Richter tells investors in a research note. The analyst views Precision as a "key player" in the allogeneic CAR-T landscape.
04/22/19
JPMS
04/22/19
INITIATION
Target $23
JPMS
Overweight
Precision BioSciences initiated with an Overweight at JPMorgan
JPMorgan analyst Eric Joseph started Precision BioSciences with an Overweight rating and $23 price target.
04/22/19
JPMS
04/22/19
INITIATION
Target $23
JPMS
JPMorgan sees 'best-in-class' potential for Precision, starts with Overweight
JPMorgan analyst Eric Joseph initiated coverage of Precision BioSciences with an Overweight rating and $23 price target. The company is "adroitly poised on multiple fronts in the precision medicine arena with its proprietary genome editing platform," Joseph tells investors in a research note. Whereas existing industry genome editing technologies to date face challenges in editing efficiency, specificity and scale, Precision's programmable meganuclease platform "looks to be a leader in each of these dimensions," says the analyst. He believes Precision has "best-in-class allogeneic CAR T platform potential."
04/22/19
JEFF
04/22/19
INITIATION
Target $25
JEFF
Buy
Precision BioSciences initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Precision BioSciences with a Buy rating and $25 price target. The analyst believes the company's proprietary gene-editing technology and platform should provide long-term value.
RHHBY Roche
$0.00

(0.00%)

05/23/19
RBCM
05/23/19
NO CHANGE
Target $143
RBCM
Outperform
RBC sees 'interesting parallels' between Intercept and Roche-acquired InterMune
RBC Capital analyst Brian Abrahams said in a new note to investors that he sees "a number of interesting parallels" between Intercept (ICPT) and InterMune, which he notes was acquired by Roche (RHHBY) for $8.3B in 2014. While he admits that "it is not a perfect apples-to-apples comparison," he highlights that both companies' lead drugs had tolerability questions and finite exclusivity periods and that competitive risks have been "overly hyped" for Intercept's obeticholic acid and InterMune's Esbriet. The analyst, who contends that the similarities "further highlight the significant valuation disconnect" for Intercept, keeps an Outperform rating and $143 price target on the shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $39
PIPR
Overweight
Roche approval has positive read through for MorphoSys, says Piper Jaffray
Roche's (RHHBY) accelerated approval of Polivy two months ahead of its FDA action date has a positive read through to MorphoSys' (MOR) MOR208, Piper Jaffray analyst Danielle Brill tells investors in a research note. While not a perfect comparison, the approval further signifies progression free survival data are not the most important efficacy measure for MOR208, adds the analyst. Further, she still thinks MOR208's efficacy and safety profile "appears distinctively better" than Polivy's. Brill remains confident for accelerated approval of MOR208 and believes that it could warrant a premium price-tag to Polivy's estimated average of $90,000 every four months. She reiterates an Overweight rating on MorphoSys shares with a $39 price target.
06/11/19
JANY
06/11/19
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said he does not see any fundamental reason for today's weakness in shares of uniQure (QURE), attributing the pullback as likely due to profit taking following some recent strong performance. Roche's (RHHBY) deal to buy Spark Therapeutics (ONCE) in February had a positive impact on the overall gene therapy sector and investor speculation has contributed to an over 30% increase in uniQure shares over the past two weeks, noted Zhong, who said his valuation does not include any acquisition assumption or premium. The analyst, who sees uniQure having the first FDA approval for an AAV gene therapy for hemophilia B and the first AAV gene therapy program in the clinic for Huntington's disease, keeps a Buy rating on the stock and would be a buyer amid today's weakness.

TODAY'S FREE FLY STORIES

04:00
06/18/19
06/18
04:00
06/18/19
04:00
General news
EGB yields decline with Treasury rates »

EGB yields decline with…

03:15
06/18/19
06/18
03:15
06/18/19
03:15
General news
FX Action: USD-CAD has settled near 1.3400 »

FX Action: USD-CAD has…

02:45
06/18/19
06/18
02:45
06/18/19
02:45
General news
FX Update: Sterling has hit fresh lows, and the yen has remained bid »

FX Update: Sterling has…

02:00
06/18/19
06/18
02:00
06/18/19
02:00
General news
Asian Market Wrap »

Asian Market Wrap:…

GE

General Electric

$10.04

-0.2 (-1.95%)

21:05
06/17/19
06/17
21:05
06/17/19
21:05
Periodicals
General Electric to cut another 450 jobs in Switzerland, Reuters says »

General Electric will lay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$86.25

-1.52 (-1.73%)

20:00
06/17/19
06/17
20:00
06/17/19
20:00
Hot Stocks
Arthur J. Gallagher acquires P2 Group, terms not stated »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

AGLNF

AGL Energy

$0.00

(0.00%)

19:28
06/17/19
06/17
19:28
06/17/19
19:28
Upgrade
AGL Energy rating change at Macquarie »

AGL Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

, RUN

Sunrun

$17.09

0.64 (3.89%)

19:02
06/17/19
06/17
19:02
06/17/19
19:02
Upgrade
SunPower, Sunrun, SolarEdge rating change at Goldman Sachs »

SunPower, Sunrun upgraded…

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

SEDG

SolarEdge

$56.58

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

, PHAS

PhaseBio

$12.25

0.74 (6.43%)

18:48
06/17/19
06/17
18:48
06/17/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: MoneyGram (MGI)…

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

PHAS

PhaseBio

$12.25

0.74 (6.43%)

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

CALA

Calithera Biosciences

$5.87

0.64 (12.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 18

    Jun

  • 19

    Jun

AAPL

Apple

$193.90

1.06 (0.55%)

18:44
06/17/19
06/17
18:44
06/17/19
18:44
Periodicals
Apple's tvOS 13 beta 2 includes Picture-in-Picture support, 9to5Mac reports »

Apple's tvOS 13 beta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$56.58

0.09 (0.16%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change at Goldman Sachs »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change at Goldman Sachs »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change at Goldman Sachs »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change at UBS »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.